Characteristics of Systemic Sclerosis patients with positive anti-Th/To antibodies: About 6 patients and literature review.

Anti-Th/To antibodies Anti-Th/To autoanticorps Atteinte interstitielle pulmonaire Forme cutanée limitée Interstitial lung disease Limited cutaneous form Sclérodermie Systémique Systemic Sclerosis

Journal

La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 18 09 2019
revised: 11 12 2019
accepted: 23 12 2019
pubmed: 18 2 2020
medline: 17 12 2020
entrez: 18 2 2020
Statut: ppublish

Résumé

Among the antibodies described in Systemic Sclerosis (SSc), anti-Th/To antibodies (anti-Th/To) are rare and have been poorly studied. Thus, little is known about the profile of anti-Th/To positive patients. From our local Biobank (Marseille, France), we retrospectively selected data for 6 patients positive for anti-Th/To with an Immunodot assay. All of them suffered from SSc, sharing clinical and biological common features such as a limited cutaneous form of SSc, a decreased lung diffusing capacity and a speckled nuclear nucleolar immunofluorescence pattern of antinuclear antibodies screening on HEp-2 cells. In order to further characterize patients positive for anti-Th/To, we performed a thorough literature review. From 402 studied patients positive for anti-Th/To, we confirmed that these antibodies are associated with the limited cutaneous form of the disease (88% of the patients), and with an SSc related-pulmonary involvement (50%). The review analysis pointed out the rarity of the anti-Th/To with an estimated mean frequency of 3.4% of all SSc patients worldwide, their usual exclusivity with respect to the specific antibodies of scleroderma, and their high specificity (around 98%) for the diagnosis of SSc.

Identifiants

pubmed: 32063422
pii: S0248-8663(20)30008-4
doi: 10.1016/j.revmed.2019.12.020
pii:
doi:

Substances chimiques

Antibodies, Antinuclear 0
Autoantibodies 0
Ribonucleoproteins 0
Endoribonucleases EC 3.1.-

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

440-445

Informations de copyright

Copyright © 2020 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

R Muller (R)

Pôle MICA, service de médecine interne, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.

A Benyamine (A)

Pôle MICA, service de médecine interne, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Inserm, INRA, C2VN, Aix-Marseille Université, Marseille, France.

D Bertin (D)

Laboratoire d'immunologie, hôpital de La Conception, Assistance Publique Hôpitaux de Marseille (AP-HM), Marseille, France.

J-R Harlé (JR)

Pôle MICA, service de médecine interne, Hôpital de La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.

G Kaplanski (G)

Pôle MICA, service de médecine interne et immunologie clinique, hôpital de La Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.

K Mazodier (K)

Pôle MICA, service de médecine interne et immunologie clinique, hôpital de La Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.

M Reynaud-Gaubert (M)

Service de pneumologie, Hôpital Nord, centre de compétence national des maladies respiratoires rares, Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix Marseille Université, Marseille, France.

B Granel (B)

Pôle MICA, service de médecine interne, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Inserm, INRA, C2VN, Aix-Marseille Université, Marseille, France. Electronic address: brigitte.granel@ap-hm.fr.

N Bardin (N)

Inserm, INRA, C2VN, Aix-Marseille Université, Marseille, France; Laboratoire d'immunologie, hôpital de La Conception, Assistance Publique Hôpitaux de Marseille (AP-HM), Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH